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Brief Definitive Report
Wounds to the skin heal via a complex series of 
overlapping tightly regulated phases. With increas­
ing age these become disrupted, and repair effi­
ciency is reduced. Chronically impaired healing in 
the elderly is a major area of unmet clinical need 
that constitutes a substantial drain on global health 
services and leads to significant patient morbidity. 
In women the transition to delayed healing coin­
cides  with  menopause,  where  hormone  levels,   
particularly estrogen, rapidly fall. We have previ­
ously reported that estrogen replacement substan­
tially accelerates healing in both aged humans and   
estrogen­depleted animal models (Ashcroft et al., 
1997).  Moreover,  estrogen  protects  against  the   
development of chronic nonhealing wounds   
(Margolis et al., 2002). We currently believe es­
trogen to be a key pleiotropic factor (Emmerson   
et al., 2009), beneficially influencing a range of 
cutaneous cell types involved in multiple aspects 
of wound repair including inflammation, re­ 
epithelialization, angiogenesis, matrix deposition, 
and remodelling. In fact, at the level of gene ex­
pression, estrogen appears more important than 
intrinsic ageing in the ontogenesis of pathological 
repair (Hardman and Ashcroft, 2008). Unfortu­
nately, recent research has highlighted the poten­
tial detrimental impact of long­term hormone 
replacement therapy (HRT) use, namely an in­
creased risk of breast cancer, stroke, and coronary 
heart disease (Anderson et al., 2004). Thus, there is 
a fundamental need to further elucidate cutane­
ous estrogen signaling with a view to selectively 
exploit the beneficial aspects to promote healing.
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Post-menopausal women have an increased risk of developing a number of degenerative 
pathological conditions, linked by the common theme of excessive inflammation. Systemic 
estrogen replacement (in the form of hormone replacement therapy) is able to  
accelerate healing of acute cutaneous wounds in elderly females, linked to its potent  
antiinflammatory activity. However, in contrast to many other age-associated pathologies, 
the detailed mechanisms through which estrogen modulates skin repair, particularly the cell 
type–specific role of the two estrogen receptors, ER and ER, has yet to be determined. 
Here, we use pharmacological activation and genetic deletion to investigate the role of 
both ER and ER in cutaneous tissue repair. Unexpectedly, we report that exogenous 
estrogen replacement to ovariectomised mice in the absence of ER actually delayed 
wound healing. Moreover, healing in epidermal-specific ER null mice (K14-cre/ERL2/L2) 
largely resembled that in global ER null mice. Thus, the beneficial effects of estrogen on 
skin wound healing are mediated by epidermal ER, in marked contrast to most other 
tissues in the body where ER is predominant. Surprisingly, agonists to both ER and ER 
are potently antiinflammatory during skin repair, indicating clear uncoupling of inflammation 
and overall efficiency of repair. Thus, estrogen-mediated antiinflammatory activity is not 
the principal factor in accelerated wound healing.
©  2010  Campbell  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
ER isoform-selective agonists confer contrasting effects  
on skin repair
In light of severely limited mouse ER expression data in   
the literature we first profiled receptor localization in mouse 
skin. We report that both receptors are widely expressed, 
with immunohistochemical localization to keratinocytes, 
hair follicles, fibroblasts, and endothelial and inflammatory cells   
(Fig. S1). To address the independent contribution of each 
receptor to skin repair we systemically treated estrogen­deprived 
mice with agonists specific for ER or ER and generated 
incisional wounds. After 3 d the degree of in vivo repair was 
quantified with respect to ovariectomised (Ovx) mice (Fig. 1, 
A–C). DPN (a 70­fold selective ER agonist) significantly 
reduced wound area, to a level comparable with that of 17­
estradiol, simultaneously promoting restoration of the epi­
dermis.  In  stark  contrast,  signaling  through  ER  (PPT 
treatment; 410­fold selective ER agonist) had no effect on 
these global measures of healing.
Intriguingly, both agonists were equally antiinflammatory 
with respect to wound macrophage and neutrophil recruit­
ment (Fig. 1, D–F). ER­mediated effects on inflammation are 
important for numerous other body systems: the ER ag­
onist PPT is both neuroprotective and antiinflammatory   
in neurodegenerative disorders such as Alzheimer’s disease 
(Tiwari­Woodruff  et  al.,  2007);  ER  mediates  the  pro­
tective effect of estrogen on skin necrosis in a skin flap per­
fusion model (Toutain et al., 2009). Notably, in the brain   
ER  agonist  treatment  has  no  antiinflammatory  effects   
(Tiwari­Woodruff et al., 2007), although Toutain et al. (2009) 
unfortunately failed to investigate the role of ER in their 
skin  flap  model.  Our  agonist  treatment  data  show  that   
although signaling through ER alone is sufficient to re­
duce skin inflammation in vivo, as widely reported in other 
tissues, it does not accelerate wound repair. Thus, we identify 
a clear uncoupling of inflammation and repair in the context 
of ER signaling. Current thinking would suggest a tightly   
regulated inflammatory response is essential to appropriate 
repair, with either excessive inflammation (chronic wounds) 
or macrophage ablation leading to delayed healing (Mirza   
et al., 2009).
ER null mice display a profound wound-healing phenotype
The next logical step was to investigate the effect of ER­ 
specific deletion. Thus, incisional wounds were generated   
in wild­type (WT), ER null (ER/), and ER null 
(ER/) mice, in the absence of estrogen (Ovx) or after ex­
ogenous estrogen replacement (Ovx plus s.c. 17­estradiol 
pellet). Healing was delayed in the absence of estrogen in all 
three genotypes (Fig. 2, A, C, and D), implying a limited role 
for ER signaling in the absence of a ligand. However, upon 
exogenous  estrogen  replacement  a  clear  genotype­specific 
response was revealed, with ER/ wounds substantially 
increased in size (Fig. 2, A–C). Delayed healing in ER/ 
corroborates our ER isoform­specific agonist treatment data 
(Fig. 1; where DPN­mediated acceleration indicates the   
In  both  mice  and  humans,  estrogen  signals  through 
two related but distinct nuclear hormone receptors, es­
trogen receptor (ER)  and , which function as either 
homo­ or hetero­dimers. The receptors, which share >95%   
homology  in  their  DNA­binding  domain,  are  differen­
tially expressed throughout mammalian tissues (for review 
see Dahlman­Wright et al., 2006). In human skin ER iso­
form distribution reportedly varies depending on cell type, 
source, and time: ER is suggested to be the predominant 
isoform  in  human  scalp  keratinocytes  (Thornton  et  al., 
2003b); although other studies describe both receptors in 
neonatal  foreskin­derived  keratinocytes  (Verdier­Sevrain 
et al., 2004), dermal fibroblasts (Haczynski et al., 2004), and 
hair follicles and sebaceous glands (Thornton et al., 2003a). 
Despite  detailed  knowledge  of  human  skin  ER  distri­
bution,  but  curiously  not  mouse,  understanding  of  the 
role that each receptor plays in cutaneous healing is se­
verely lacking.
Agonists selective for each estrogen receptor are cur­
rently being used in vivo to elucidate the specific roles of 
ER isoforms in a range of tissues. In addition, several iter­
ations of ER null mice have been generated, each improv­
ing upon the previous, after initial issues with lack of splice 
variant deletion (for review see Antal et al., 2008). These 
mice have been extensively characterized with phenotypes 
reported in a range of tissues. Both ER/ and ER/ 
mice display pronounced reproductive phenotypes (for re­
view see Couse and Korach, 1999). In peripheral tissues, 
however, ER appears to predominate, with ER/ mice 
displaying abnormalities in mammary, bone, neurological, 
vascular, metabolic, and other tissues. Thus, although ER 
is clearly of fundamental physiological importance, the re­
spective role of ER is more contentious. Despite numer­
ous reports describing pathological phenotypes in global 
ER/ mice (for review see Couse and Korach, 1999), a 
recently generated constitutive­Cre ER(L/L) null mouse 
appears  virtually  devoid  of  peripheral  tissue  pathology 
(Antal et al., 2008).
The limited data that does exist on the role of ERs in   
the skin is mostly based around studies of hair biology. In 
male mice, hair cycling appears mediated by ER, whereas 
catagen transition is ER regulated (Movérare et al., 2002;   
Ohnemus et al., 2005). Recently the protective effect of es­
trogen on skin flap necrosis has been reported to be mediated 
by ER (Toutain et al., 2009). To date, however, no study 
has investigated the effect of ER­specific deletion, or the 
role of ER isoforms in skin wound healing in female mice.   
In this study, using a combination of in vivo and in vitro 
methodologies, we demonstrate very different roles for the 
two ERs during skin wound healing. Specifically, the benefi­
cial effects of estrogen in skin are mediated through ER, 
with signaling through ER alone having a detrimental in­
fluence on repair. To our knowledge, skin healing is unique 
in that it is the first tissue where; (a) ERs have been demon­
strated to have such clearly opposed physiological effects and 
(b) ER­mediated influence is so predominant.JEM VOL. 207, August 30, 2010  1827
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Estrogen is potently antiinflammatory in WT mice, in­
hibiting local wound recruitment of innate immune cells   
in vivo (Fig. 2, E–H) and dampening lipopolysaccharide­ 
induced cytokine production in vitro (Emmerson et al., 2009). 
Immunohistochemical characterization of wound cell infil­
trate in ER null mice revealed key quantitative differences   
in local inflammation. Estrogen replacement in ER/  
mice failed to dampen inflammation, whereas ER/ mice 
were characterized by a significant and specific increase in 
wound neutrophils (Fig. 2, E–H). It is generally accepted that 
excessive neutrophil infiltration plays a causative role in patho­
logically delayed healing; however, the role of macrophages 
importance of ER). Mechanistically, estrogen can modulate 
keratinocyte, fibroblast, and inflammatory cell functions. Thus, 
delayed healing in estrogen­treated ER/ mice may reflect 
defective wound contraction, delayed re­epithelialization, ex­
cessive inflammation, altered angiogenesis, or a combination 
of these processes.
Figure 2.  Exogenous estrogen treatment delays wound healing in 
ER null (ER/) mice. (A and B) Representative morphology and 
histology at d 3 after wounding. (arrows indicate wound margins).  
(C) Wound area quantification reveals delayed healing in Ovx ER/ 
mice after 17-estradiol treatment (E). (D) Estrogen fails to accelerate re- 
epithelialization in ER null (ER/) or ER/ mice. (E–H) Quantification 
of wound inflammatory cells, with representative immunohistochemistry  
(E and F), reveals increased neutrophil numbers in estrogen-treated 
ER/ mice. Data shown as mean ± SEM are representative of two  
independent experiments (n = 5–7). (B) “ER/+E” image has been auto 
stitched from two individual images. Bars: (A) 6 mm; (B) 600 µm;  
(E and F) 150 µm. Black asterisk, P < 0.05; red asterisk, P < 0.01.
Figure 1.  The ER agonist, DPN, accelerates wound healing.  
(A) Representative H&E-stained sections of full-thickness incisional 
wounds (d 3) from mice with intact ovaries, ovariectomised (Ovx), and Ovx 
mice systemically treated with 17-estradiol (E), DPN (ER agonist), or 
PPT (ER agonist) (arrows indicate wound margins). (B and C) DPN accel-
erates healing equally to 17-estradiol quantified by reduced wound area 
(B) and increased re-epithelialization. (D and E) Both PPT and DPN are 
potently antiinflammatory when compared with untreated Ovx mice.  
(F) Representative immunohistochemistry for wound neutrophils and 
macrophages, respectively. Data shown as mean ± SEM are representative 
of two independent experiments (n = 6). Bar, 200 µm (A); 50 µm (F). Black 
asterisk, P < 0.05; red asterisk, P < 0.01 with respect to Ovx.1828 Estrogen receptor  promotes wound healing | Campbell et al.
provide an additional new model to investi­
gate such yin­yang ER interactions.
Delayed healing in global ER/ is 
recapitulated in epidermal-specific ER 
null mice in the absence of  
excessive inflammation
Estrogen is a known keratinocyte mitogen 
(Emmerson et al., 2009), yet paradoxically, 
neither  ER/  nor  ER/  mice  dis­
played increased re­epithelialization after estrogen treatment   
(Fig. 2 D). Mouse keratinocytes express both ERs (Fig. S1) with 
a recent report indicating that agonists specific for either ER 
can promote the in vitro migration of the human keratino­
cyte cell line NCTC 2544 (Merlo et al., 2009). To further   
investigate  mouse  epidermal  ER  function  we  wounded   
epidermal­specific (K14­cre) knockout mice, K14-cre/ERL2/L2 
(K14­ER),  K14-cre/ERL2/L2  (K14­ER),  and WT  litter 
mates. Estrogen treatment of Ovx K14­ER mice led to pro­
nounced and significant acceleration of re­epithelialization 
(Fig. 3 C). In contrast, estrogen treatment of Ovx K14­ER 
mice failed to promote re­epithelialization (Fig. 3 C) and led 
to a significant delay in overall healing (Fig. 3, A and B). Com­
parison of the temporal healing profile between estrogen­
treated K14­ER and WT mice shows that the observed 
difference in repair at d 3 after wounding is maintained over 
subsequent stages of healing (Fig. 3 D). That K14­ER mice 
essentially phenocopy global ER/ mice indicates estrogen’s 
beneficial influence on healing is predominantly mediated by 
epidermal ER, and presumably involves paracrine signal­
ing to additional cell types (e.g., vascular, fibroblast) that also 
functionally influence the healing response.
In this context it is interesting to draw comparisons to other 
tissues where complex stromal–epithelial interactions occur, 
such as mammary gland or prostate. The mammary gland un­
dergoes highly orchestrated morphological change during de­
velopment and pregnancy, for which epithelial–mesenchymal 
appears  more  subtle  (Diegelmann,  2003).  Recent  studies 
have revealed macrophages to be beneficial only at specific 
stages of tissue repair (Mirza et al., 2009). It is tempting to 
speculate that increased neutrophil numbers could play a role 
in the delayed healing of the ER/ mouse phenotype.
Collectively, these in vivo data strongly suggest that sig­
naling though ER in the absence of ER is in fact detri­
mental to healing. Moreover, we observed marked differences 
between agonist­treated mice (allowing ER heterodimeriza­
tion) and ER null mice (exclusively ER homodimers). For 
example, the ER agonist DPN strongly promoted re­ 
epithelialization in vivo (Fig. 1), whereas estrogen treatment 
of ovariectomised ER/ mice (Fig. 2) did not alter re­ 
epithelialization. Thus, signaling through ER leads to en­
tirely different phenotypes depending on the presence or 
absence of ER. This implies that a proportion of skin ER­
mediated effects are through ER inhibition or alternatively 
that ER heterodimers are physiologically important. Such 
“yin­yang” ER interactions have been classically described   
in cancer, which is fascinating as clear analogies have been 
drawn between cancer progression and tissue repair (Dvorak, 
1986). ER classically promotes tumor proliferation through 
regulation of the cell cycle, whereas ER is anti­proliferative 
(Paruthiyil et al., 2004). Indeed, it has been proposed, but not 
shown, that many of the physiological effects of ER in other 
tissues are in fact due to direct antagonistic effects on ER­
mediated transcription (Lindberg et al., 2003). Skin could 
Figure 3.  Epidermal-specific ER null  
(K14-ER) mice phenocopy ER/ mice.  
(A) Representative H&E-stained sections from estro-
gen (E)-treated wild-type (WT), K14-ER, and  
K14-ER mice. (B and C) Estrogen treatment of  
K14-ER mice specifically delays healing, shown by 
increased wound area (B) with no increase in re-
epithelialization (C). (D) Temporal monitoring of exci-
sional wound closure reveals that delayed healing 
(K14-ER) is maintained through later time points.  
(E and F) Quantification of wound inflammatory cell 
numbers reveals antiinflammatory effects for estro-
gen on neutrophils in WT and K14-ER (E). Data 
shown as mean ± SEM are representative of two 
independent experiments (n = 6). (A) “K14-ER+E” 
image has been auto stitched from two individual 
images. Bars: (A) 400 µm; (D) 4 mm. Black asterisk,  
P < 0.05; red asterisk, P < 0.01.JEM VOL. 207, August 30, 2010  1829
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In our primary keratinocytes both 17­estradiol 
and DPN, but not PPT, significantly increased 
adhesion to noncoated (Fig. 4 C) and collagen­
coated (unpublished data) tissue culture plates. 
Interestingly, the migration/adhesion effects are proliferation 
independent, as proliferation rate is not influenced by either 
17­estradiol or ER agonists (Fig. 4 D).
ER isoforms differentially regulate fibroblast migration in vitro
Fibroblasts  represent  an  excellent  candidate  cell  type  for 
nonkeratinocyte­mediated effects of ERs on wound heal­
ing, with estrogen known to influence multiple skin fibro­
blast functions (Emmerson et al., 2009). As the observed   
in vivo delayed healing phenotype in ER/ mice (Fig. 2)   
involved substantial wound gaping, we asked whether ER­
mediated effects on fibroblast contraction could be involved. 
In a cell­based contraction assay 17­estradiol, DPN, or PPT 
treatment all inhibited collagen disc contraction (Fig. 5 A), 
suggesting that signaling through ER versus ER was un­
likely to differentially alter contraction in vivo. Moreover, equal 
numbers of ­smooth muscle actin (SMA)–positive cells were 
observed in WT and global ER/ and ER/ wounds 
in vivo (Fig. 5 B). Although these data suggest minimal in­
volvement of fibroblast­mediated contraction, the observed 
phenotype (wound gaping) does suggest inherent differences 
in tensional forces upon wounding. Wound contraction is a 
complex process that is also affected by numerous factors, 
for example balance between collagen synthesis and deposi­
tion, and thus early changes may be involved in the ob­
served phenotype.
We have previously shown that 17­estradiol treatment 
accelerates WT mouse fibroblast migration in vitro (Emmerson 
et al., 2009). The ER agonist DPN also substantially accel­
erated in vitro scratch assay migration, whereas the ER  
agonist PPT had no significant effect (Fig. 5, C and D).   
Receptor­specific function was confirmed by cotreatment 
with 17­estradiol and ER­specific antagonists (Fig. 5 D); 
blocking  both  ERs  (ICI)  abolished  estrogen­promoted   
migration; specifically blocking ER (MPP) led to dramati­
cally  accelerated  migration  (>  twofold  increase),  whereas 
specifically blocking ER (PHTPP) had no significant effect 
on estrogen’s migration promoting ability. As in keratino­
cytes, these treatments had no effect on fibroblast prolifera­
tion (Fig. 5 E), indicating that altered proliferation does not 
contribute to the migration­promoting effects of 17­estradiol 
cross talk is absolutely essential. ER null mouse experi­
ments  indicate  that  ER  triggers  ductal  growth,  whereas 
ER is involved much later in terminal differentiation. In­
terestingly, although ER expression in mammary epithe­
lium is heterogeneous, estrogen induces proliferation in   
all epithelial cells, implying paracrine effects on ER­negative 
epithelial cells (Mallepell et al., 2006). Amphiregulin, an EGF 
receptor ligand, is a prime candidate for mediating these effects 
in vivo. Similar keratinocyte–keratinocyte and keratinocyte– 
fibroblast interactions almost certainly occur during skin wound 
healing, where EGF/FGF receptors play a well­documented 
role. However, our data suggest that ER is the key player in 
these epithelial–mesenchymal events.
Fascinatingly, the inflammatory response in delayed­healing 
wounds from epidermal­specific K14­ER mice appeared 
equivalent to that in WT mice (Fig. 3, E and F). That K14­
ER mice display delayed healing concomitant with reduced 
inflammation provides yet more evidence for uncoupling of 
inflammation and healing. Moreover, this phenotype strongly 
suggests that inflammatory cell changes (i.e., increased neu­
trophil infiltration) are not a principal causative factor in de­
layed healing in global ER/ mice (Fig. 2 H). To investigate 
this further we wounded mice with LysM­cre–mediated in­
flammatory cell­specific deletion of ER (Fig. S2). These 
mice were essentially phenotypically normal with reduced 
wound area and dampened inflammation in response to es­
trogen treatment. This strongly implies that inflammatory 
cell­specific ER does not contribute to the global ER/ 
delayed wound healing phenotype, reinforcing the impor­
tance of keratinocyte­expressed ER in estrogen’s beneficial 
effects on wound healing.
To further clarify the role of each ER in keratinocyte 
function we performed in vitro scratch wound migration assays. 
Treatment of WT keratinocytes with the ER agonist DPN 
promoted migration, whereas the ER agonist PPT had no 
influence on scratch wound closure (Fig. 4, A and B). These 
data fit perfectly with in vivo agonist treatment (Fig. 1 D) and 
epidermal­specific ER deletion data (Fig. 3 C). It is unclear 
why Merlo et al. (2009) report enhanced in vitro migration in 
response to both PTT and DPN.  They used a cell line, whereas 
we used more physiologically relevant primary keratinocytes. 
Figure 4.  Estrogen modulates mouse keratinocyte 
function through ER in vitro. (A and B) ER agonist 
(DPN; 10-6M) promotes keratinocyte migration to the 
same extent as 17-estradiol (E; 10-7 M), whereas ER 
agonist (PPT; 10-6M) has no effect. (C) Keratinocyte  
attachment is increased with E and DPN treatment.  
(D) E, DPN, or PPT treatment has no effect on prolifera-
tion after 48 h. Data shown as mean ± SEM, in triplicate 
wells, and are representative of two independent experi-
ments. Bar: (A) 300 µm. *, P < 0.05; **, P < 0.01.1830 Estrogen receptor  promotes wound healing | Campbell et al.
in chronic wounds, and play an important role in granula­
tion tissue remodelling (Wysocki et al., 1993). Though we 
have previously reported increased MMP­9 protein levels in   
delayed­healing Ovx mouse wounds (Emmerson et al., 2009), 
we have not explored the effect of in vivo 17­estradiol treat­
ment on wound protease activity. Collectively, these data   
suggest that inappropriately excessive local gelatinase activity 
is a principal contributing factor to reduced collagen deposi­
tion and delayed wound healing in ER/ mice. However, 
the phenotypes of estrogen­treated LysM­ER (Fig. S2) and 
K14­ER (Fig. 3) mice suggests that increased inflammation 
and protease activity in estrogen­treated ER/ mice is in 
fact secondary to delayed healing (i.e., noncausative), once 
again indicating complex paracrine interactions. Of note, by 
d 7 after wounding this ER­specific difference in collagen 
deposition, assessed by Picro­Sirius red staining, was no   
longer apparent (unpublished data), indicating the observed   
d 3 phenotype is due to an extended lag­phase of healing in 
the ER/ mice (see also Fig. 3 D), possibly due to differ­
ences in wound contraction (see Fig. 5).
In summary, our novel data reveal the beneficial effects 
of estrogen on skin healing to be predominantly mediated 
though keratinocyte ER (Fig. S3). This fascinating finding 
appears at odds with the recent suggestion that ER/ mice 
display relatively few global phenotypic abnormalities (Antal 
et al., 2008). Indeed, we suggest that the role of ER may 
be revealed only in response to perturbation of homeostasis 
or in pathophysiological conditions. Limited previous stud­
ies have suggested that ER plays a predominant role in 
the skin (Toutain et al., 2009). That ER has been identi­
fied as the major player during skin repair further corrobo­
rates  previous  reports  linking  specific  human  ER  gene 
polymorphisms  with  predisposition  to  chronic  nonhealing 
wounds (Ashworth et al., 2008). In light of the detrimental 
side­effects  of  estrogen  treatment  in  post­menopausal 
women, specifically increased cancer incidence, there is cur­
rently much interest in the development of estrogenic alter­
natives.  Selective  estrogen  receptor  modulators  (SERMs) 
have been, and are currently being, developed that differen­
tially bind ERs with tissue­specific agonist/antagonist pro­
files. In fact, we have recently demonstrated the potential of 
clinically relevant SERMs (tamoxifen and raloxifene) to ac­
celerate wound repair in vivo. The novel findings from this 
study are of fundamental importance and should now permit 
the development of strategies to selectively exploit benefi­
cial ER­mediated signaling events to accelerate wound 
healing in the elderly.
MATERIALS AND METHODS
Animals and wounding. All animal studies were approved by the UK 
Government Home Office (Project licence 40/3203) following local ethics 
committee approval. ER/ (Esr1) and ER/ (Esr2) have been described 
previously  (Dupont  et  al.,  2000).  Novel  conditional  ER  null  mice  were   
generated as follows. Epidermal­specific deletion of ER and ER was ob­
tained by crossing the previously described ERL2/L2 (Dupont et al., 2000) 
and ERL2/L2 (Antal et al., 2008) mice with the extensively characterized 
K14­cre line (Li et al., 2001). Inflammatory cell­specific deletion was   
or  DPN.  Thus,  promotion  of  fibroblast  migration  may   
contribute  to  the  observed  accelerated  healing  in  DPN­
treated mice (Fig. 1).
Excessive protease activity and reduced matrix deposition 
contribute to delayed healing in estrogen-treated ER/ 
mouse wounds
Altered systemic hormone levels have been linked to changes 
in skin collagen deposition and turnover during wound heal­
ing (Gilliver et al., 2007). In light of clear ER­specific effects 
on fibroblast function, we next assessed aspects of wound matrix 
synthesis, deposition, and remodeling (Fig. 6). We demonstrate 
reduced gene expression of the major skin collagen species in 
delayed­healing estrogen­treated ER/ wounds (Fig. 6 A) 
accompanied by greatly reduced wound collagen protein   
deposition/remodelling, assessed via Picro­Sirius red staining 
(Fig. 5 B). Of mechanistic importance, we show that the spe­
cific increase in wound neutrophil influx in estrogen­treated 
ER/ wounds is accompanied by an increase in inflamma­
tory cell gelatinase expression and crucially wound gelatinase 
activity (Fig. 5, C and D). Gelatinases (MMP­2 and MMP­9) 
are induced after wounding, are pathologically overexpressed 
Figure 5.  ERs differentially modulate fibroblast migration in vitro. 
(A) Fibroblast-mediated contraction of collagenous discs was inhibited by 
17-estradiol (E), ER agonist (DPN; 10-6M), or ER agonist (PPT; 10-6M). 
(B) Immunohistochemical quantification of wound -SMA. (C and D) E and  
DPN promoted fibroblast migration compared with untreated cells ().  
Co-treatment with E and the ER antagonist (ICI; 10-7 M) blocked  
migration, whereas cotreatment with ER antagonist (MMP; 10-5M) in-
creased migration. PHTPP, ER antagonist (10-5M). (E) Fibroblast prolif-
eration assay. Data shown as mean ± SEM using triplicate wells (A, C–E) 
or 5–7 animals per group (B) are representative of two independent ex-
periments. Bars: (A) 400 µm; (D) 600 mm. *, P < 0.05; **, P < 0.01.JEM VOL. 207, August 30, 2010  1831
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Gelatin zymography. Total protein was extracted from mouse wound   
tissue using denaturing, nonreducing buffer. 50 µg protein was assessed for 
gelatinase activity, as described previously (Gilliver et al., 2007). In brief, sam­
ples were separated by SDS­PAGE alongside human MMP­2 and MMP­9   
reference standards. Gels were washed in 2.5% Triton X­100 (Sigma­ 
Aldrich), incubated for 16 h at 37°C in assay buffer (100 mM Tris, 30 mM 
CaCl2, 0.02% [wt/vol], sodium azide, 0.05% [vol/vol]; Brij 35, pH 7.9) and 
stained with Coomassie brilliant blue G for 20 min and destained in 1%   
acetic acid and 30% methanol.
Primary cell assays. Keratinocytes and dermal fibroblasts were isolated 
from neonatal mice mouse skin as described previously (Emmerson et al., 
2009). Mouse macrophages were isolated by peritoneal lavage with PBS and 
cultured as described previously (Emmerson et al., 2009). Functional assays 
were performed in phenol red–free media containing charcoal­stripped   
serum and mitomycin C where appropriate. Fibroblasts were cultured in 
PSA­supplemented DMEM (Lonza) and keratinocytes in CnT­02 media 
(CELLnTEC) at 35°C and 5% CO2. Treatments (107 M 17­estradiol, 
106 M PPT, 106 M DPN, 107 M ICI 182780, 105 M MPP dihydro­
chloride, 105 M PHTPP) were consistent across all assays.
Scratch migration assay. Fibroblast or keratinocyte sheets were scratch 
wounded (sterile pipette tip) and immediately treated. Cells were incubated 
in  serum  and  PSA­supplemented  DMEM  (Lonza)  or  CnT­02  media 
(CELLnTEC) at either 37°C or 35°C and 5% CO2 for 24 h (fibroblasts) or 
48 h (keratinocytes). Images were captured on a microscope (Eclipse E600; 
Nikon) with a SPOT camera and software (Image Solutions Inc.), and 
degree of cell migration was determined using Image Pro­Plus software 
(Media Cybernetics).
Proliferation assay. Fibroblasts or keratinocytes were seeded in 96­well 
plates at a density of 5 × 103 cells/well. Cells were incubated for 48 h   
(keratinocytes) or 96 h (fibroblasts) and proliferation measured using the 
CellTiter96 AQueous MTS­based kit (Promega) relative to a calibration   
curve determined from wells known to contain between 5 × 103 and   
105 fibroblasts.
Attachment assay. Keratinocytes were incubated at 37°C and 5% CO2  
for 3 h in uncoated or collagen IV–coated (BD) 12­well plates. Unattached 
cells  were  removed  by  PBS  washes. Attached  keratinocytes  were  stained   
with  2%  crystal  violet  and  quantified  using  Image  Pro­Plus  software   
(Media Cybernetics).
Contraction assay. The contractile activity of dermal fibroblasts was as­
sessed using an established contraction assay (Emmerson et al., 2009).   
In brief, 1.5 × 106 cells/ml were resuspended in chilled collagen I matrix/
DMEM  solution  (Vitrogen  100).  Aliquots  of  this  cell/collagen/DMEM   
solution were incubated for 1 h under mineral oil in a Teflon­lined, die­cut 
obtained by crossing ERL2/L2 mice with the previously characterized 
LysM­cre line (Clausen et al., 1999). In each case, Cre­negative homozygous 
floxed mice were used as littermate controls. 10­wk­old female C57/BL6 
mice with intact ovaries and 10­wk­old C57/BL6 mice that had undergone 
ovariectomy 1 mo previously were wounded (two equidistant 1­cm full­
thickness skin incisional wounds left to heal by secondary intention or two 
6­mm excisional wounds to temporally monitor healing) following our es­
tablished protocol (Emmerson et al., 2009). PPT (4,4’,4”­(4­Propyl­[1H]­
pyrazole­1,3,5­triyl; Tocris), DPN (2,3­bis(4­Hydroxyphenyl)­propionitrile; 
Tocris), or vehicle (5% DMSO in maize oil) was injected at 330 µg/kg/day 
on days 1, 0, and +1 with respect to time of wounding. Female ER/, 
ER/,  K14­cre/ERL2/L2,  K14­cre/ERL2/L2,  LysM­cre/ERL2/L2,  and 
WT littermates were also ovariectomised and wounded as above. Exogenous 
estrogen was administered at the time of wounding by s.c. implantation of a 
0.05­mg, 21­d, slow­release 17­estradiol pellet (Innovative Research of 
America) with successful estrogen replacement confirmed by enzyme immuno­
assay on serum samples.
Histology and immunohistochemistry. Histological sections were pre­
pared from wound tissue fixed in 10% buffered formalin saline and embed­
ded in paraffin. 6­µm sections were stained with hematoxylin and eosin, 
Sirius red (in picric acid), or subjected to immunohistochemical analysis 
with the following antibodies: anti­ER rabbit polyclonal (Santa Cruz 
Biotechnology, Inc.); mouse monoclonal anti­ER (AbD Serotec); anti­
neutrophil rat polyclonal (Thermo Fisher Scientific); anti–Mac­3 rat poly­
clonal (BD); and anti–­SMA rabbit polyclonal (Sigma­Aldrich). Bound 
primary antibody was detected using the VECTASTAIN ABC kit (Vector 
Laboratories), NovaRed substrate, and counterstained with hematoxylin. 
Images were captured using a microscope (Eclipse E600; Nikon) and a 
SPOT camera (Image Solutions Inc.) and total cell numbers, granulation 
tissue wound area, and re­epithelialization were quantified using Image Pro 
Plus software (Media Cybernetics). Specifically, re­epithelialization was de­
termined by dividing the sum length of both neo­epithelial tongues by the 
distance the epidermis would have to migrate to fully close the wound. 
Picro­Sirius red staining was visualized using plane­polarized light where 
larger collagen fibers appear red, orange, or yellow and thinner fibers green. 
Excisional wound closure was determined from planimetry of macroscopic 
wound images.
Quantitative real-time PCR (qPCR). Total RNA was isolated from 
frozen wound tissue by homogenizing in Trizol reagent (Invitrogen) or 
from cultured macrophages using the RNeasy mini kit (QIAGEN) with 
cDNA synthesis, and qPCR was performed as described previously (Gilliver 
et al., 2007; SYBR Green core kit; Eurogentec). Each sample was serially 
diluted over three orders of magnitude, and expression ratios normalized to 
the mean of three separate reference primers (18s rRNA, Gapdh, and Ywahz) 
with all samples analyzed concurrently. Full primer sequences are listed   
in Table S1.
Figure 6.  Altered matrix deposition and protease 
activity in ER null (ER/) mice. (A and B) Wound 
collagen content determined by expression of major 
collagen species (qPCR) and Picro-Sirius staining was 
reduced in estrogen (E)-treated ER/ mice.  
(C) E-treated peritoneal macrophages from ER/ mice 
display increased MMP-2 and MMP-9 expression. (D) Via 
zymography, MMP-9 activity was strongly increased in  
E-treated ER/ wounds. Data from two independent 
experiments are shown as mean ± SEM using cells in 
triplicate wells (C) or four animals per group (A).  
(B and D) Representative of at least four animals per group 
from three independent experiments. (B) “ER/+E” image 
has been auto stitched from two individual images. Bar, 
800 µm. Black asterisk, P < 0.05; red asterisk, P < 0.01.1832 Estrogen receptor  promotes wound healing | Campbell et al.
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